Dulac Edward J III, EVP and Chief Financial Officer of Intellia Therapeutics Inc (NTLA), sold NTLA shares on the open market twice in the last 365 days for a total of $163 thousand. His most recent sale occurred on January 5, 2026. These sales rank 8,831st among 11,678 individual insiders in our database, where the average is $8.6 million across about 6.4 transactions per insider. Dulac Edward J III made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 1, 2026 | Intellia Therapeutics, Inc. | $NTLA | Dulac Edward J III | EVP, Chief Financial Officer | A | Stock Option (right to buy) | 87543 | $0.00 | 87,543.0000 | 115,829,926 | 9999.99% | 0.08% |
| March 1, 2026 | Intellia Therapeutics, Inc. | $NTLA | Dulac Edward J III | EVP, Chief Financial Officer | A | Common Stock | 61280 | $0.00 | 160,963.0000 | 115,829,926 | 61.47% | 0.05% |
| Jan. 5, 2026 | Intellia Therapeutics, Inc. | $NTLA | Dulac Edward J III | EVP, Chief Financial Officer | S | Common Stock | 6379 | $9.21 | 99,683.0000 | 115,829,926 | 6.01% | 0.01% |
| July 23, 2025 | Intellia Therapeutics, Inc. | $NTLA | Dulac Edward J III | EVP, Chief Financial Officer | S | Common Stock | 7462 | $14.02 | 106,062.0000 | 103,517,460 | 6.57% | 0.01% |
| March 1, 2025 | Intellia Therapeutics, Inc. | $NTLA | Dulac Edward J III | EVP, Chief Financial Officer | A | Common Stock | 47200 | $0.00 | 113,524.0000 | 103,517,460 | 71.17% | 0.05% |
| March 1, 2025 | Intellia Therapeutics, Inc. | $NTLA | Dulac Edward J III | EVP, Chief Financial Officer | A | Stock Option (right to buy) | 67429 | $0.00 | 67,429.0000 | 103,517,460 | 9999.99% | 0.07% |
| July 22, 2024 | Intellia Therapeutics, Inc. | $NTLA | Dulac Edward J III | EVP, Chief Financial Officer | A | Stock Option (right to buy) | 96219 | $0.00 | 96,219.0000 | 0 | 9999.99% | 0.00% |
| July 22, 2024 | Intellia Therapeutics, Inc. | $NTLA | Dulac Edward J III | EVP, Chief Financial Officer | A | Common Stock | 66324 | $0.00 | 66,324.0000 | 0 | 9999.99% | 0.00% |
| March 4, 2024 | FATE THERAPEUTICS INC | $FATE | Dulac Edward J III | Chief Financial Officer | S | Common Stock | 2447 | $7.77 | 101,479.0000 | 98,411,162 | 2.35% | 0.00% |
| Feb. 1, 2024 | FATE THERAPEUTICS INC | $FATE | Dulac Edward J III | Chief Financial Officer | A | Stock Option (Right to Buy) | 425000 | $0.00 | 425,000.0000 | 98,411,162 | 9999.99% | 0.43% |
| Jan. 29, 2024 | FATE THERAPEUTICS INC | $FATE | Dulac Edward J III | Chief Financial Officer | S | Common Stock | 1849 | $5.00 | 103,926.0000 | 98,411,162 | 1.75% | 0.00% |
| Jan. 9, 2024 | FATE THERAPEUTICS INC | $FATE | Dulac Edward J III | Chief Financial Officer | S | Common Stock | 7028 | $4.37 | 105,775.0000 | 98,411,162 | 6.23% | 0.01% |
| Jan. 2, 2024 | FATE THERAPEUTICS INC | $FATE | Dulac Edward J III | Chief Financial Officer | S | Common Stock | 5182 | $3.66 | 112,803.0000 | 98,411,162 | 4.39% | 0.01% |
| Dec. 18, 2023 | FATE THERAPEUTICS INC | $FATE | Dulac Edward J III | Chief Financial Officer | S | Common Stock | 1585 | $3.50 | 117,985.0000 | 0 | 1.33% | 0.00% |
| Aug. 18, 2023 | FATE THERAPEUTICS INC | $FATE | Dulac Edward J III | Chief Financial Officer | S | Common Stock | 4718 | $2.80 | 119,570.0000 | 0 | 3.80% | 0.00% |
| July 5, 2023 | FATE THERAPEUTICS INC | $FATE | Dulac Edward J III | Chief Financial Officer | S | Common Stock | 5182 | $4.83 | 124,288.0000 | 0 | 4.00% | 0.00% |
| Feb. 6, 2023 | FATE THERAPEUTICS INC | $FATE | Dulac Edward J III | Chief Financial Officer | A | Stock Option (Right to Buy) | 425000 | $0.00 | 425,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 10, 2023 | FATE THERAPEUTICS INC | $FATE | Dulac Edward J III | Chief Financial Officer | S | Common Stock | 7331 | $5.24 | 129,470.0000 | 0 | 5.36% | 0.00% |